Scholarlink

Purpose <p>To screen drug targets of ovarian aging from a&#xa0;genetic perspective.</p> Methods <p>Systematic analyses were conducted with cis-expression quantitative trait loci data of druggable genes extracted as instrument variables. Summary statistics were from large genome-wide association studies for age at menopause. The following colocalization analysis was utilized to examine whether identified genes and ovarian aging shared causal variants. Furthermore, clinical validation was conducted by comparing expression of identified genes in granulosa cells from women with normal or diminished ovarian reserve (DOR) who went through in vitro fertilization (IVF) and by evaluating correlation of targeted gene expression with ovarian function and IVF outcomes. Moreover, single-nuclear RNA (snRNA) seq and drug database were analyzed to find target cells within the ovary and potential drugs targeting identified genes.</p> Results <p>Systematic analyses identified five therapeutic targets of ovarian aging, including four protective factors (<i>BRCA1</i>, <i>KLHL18</i>, <i>PNP</i>, <i>SRPK1</i>) and one risk factor (<i>PDIA3</i>). The change in expression level of four protective factors has been verified in clinical validation. Particularly, both <i>BRCA1</i> and <i>SRPK1</i> have been downregulated among advanced-aged women with DOR and were positively correlated with anti-Müllerian hormone and antral follicle count. Specific target cells and potential small molecule targeted drugs of these genes were identified through snRNA analysis and searching in the drug database.</p> Conclusions <p>By systematic genetic analyses combined with clinical validation, we identified five potential druggable genes for ovarian aging, providing theoretical basis and promising direction of therapeutic genetic targets for ovarian aging in the future.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification of potential therapeutic targeting in ovarian aging from genetic screening with clinical validation

  • 期刊论文

  • 发表日期：

    2025年5月9日

查看全文
  • Xiangfei Wang,
  • Ruolin Mao,
  • Rui Long,
  • Limin Gao,
  • Meng Wang,
  • Juepu Zhou,
  • Kun Qian,
  • Lixia Zhu,
  • Lei Jin

摘要

Purpose

To screen drug targets of ovarian aging from a genetic perspective.

Methods

Systematic analyses were conducted with cis-expression quantitative trait loci data of druggable genes extracted as instrument variables. Summary statistics were from large genome-wide association studies for age at menopause. The following colocalization analysis was utilized to examine whether identified genes and ovarian aging shared causal variants. Furthermore, clinical validation was conducted by comparing expression of identified genes in granulosa cells from women with normal or diminished ovarian reserve (DOR) who went through in vitro fertilization (IVF) and by evaluating correlation of targeted gene expression with ovarian function and IVF outcomes. Moreover, single-nuclear RNA (snRNA) seq and drug database were analyzed to find target cells within the ovary and potential drugs targeting identified genes.

Results

Systematic analyses identified five therapeutic targets of ovarian aging, including four protective factors (BRCA1, KLHL18, PNP, SRPK1) and one risk factor (PDIA3). The change in expression level of four protective factors has been verified in clinical validation. Particularly, both BRCA1 and SRPK1 have been downregulated among advanced-aged women with DOR and were positively correlated with anti-Müllerian hormone and antral follicle count. Specific target cells and potential small molecule targeted drugs of these genes were identified through snRNA analysis and searching in the drug database.

Conclusions

By systematic genetic analyses combined with clinical validation, we identified five potential druggable genes for ovarian aging, providing theoretical basis and promising direction of therapeutic genetic targets for ovarian aging in the future.